Biotech drugmaker Amgen Inc. said that a U.S. court upheld the patents supporting its hyperparathyroidism drug Sensipar, blocking a competitor from selling a generic version of the drug until 2018.
The U.S. Food and Drug Administration is warning the public about criminals posing as FDA special agents and other law enforcement personnel as part of a continued international extortion scam.
The Wall Street Journal has reported that the biotech drugmaker, Genzyme Corp., is discussing a more lucrative deal with French giant Sanofi-Aventis, which has been unsuccessfully pursuing the company since last July.
BioTek's EL406 Microplate Washer Dispenser may now be used for automated vacuum filtration processes with the EL406 vacuum filtration module. BioTek's microplate washers can now be used for automated washing of assays such as the Luminex xMAP.
Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced that Cygnus Technologies Inc. and Radix Biosolutions have launched kits specifically designed for compatibility with the company’s immunoassay platform.
Emerald BioStructures has successfully achieved the second milestone in its collaboration with UCB on the structure-based discovery of small molecule modulators of undisclosed targets.
Receptos, Inc., a biopharmaceutical company, announces grant of license and technology transfer to Ortho-McNeil-Janssen Pharmaceuticals, Inc. for Receptos’s breakthrough GPCR crystal structure determination technology.
Using a new technology that relies on thousands of synthetic molecules to fish for disease-specific antibodies, researchers have developed a potential method for detecting Alzheimer's disease with a simple blood test.
The team of researchers created genetic sequences never before seen in nature, and the scientists showed that they can produce substances that sustain life in cells almost as readily as proteins produced by nature's own toolkit.
Johnson & Johnson said that it requested approval to sell its blood thinner rivaroxaban for the prevention of stroke and embolism in patients with atrial fibrillation. The company said it filed for marketing approval with the Food and Drug Administration.
BIND Biosciences announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014 is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.
AstraZeneca PLC says the U.S. Food and Drug Administration will take more time to review the British company's application for vandetanib, a drug it is developing as a treatment for a rare type of thyroid cancer.
A team of researchers has identified specific bacteria that may have a key role in vascular pathogenesis, specifically atherosclerosis, or what is commonly referred to as "hardening of the arteries" – the number one cause of death in the United States.
Cancer cells reproduce by dividing in two, but a molecule known as PML limits how many times this can happen. Malignant cancers have problems with this molecule, meaning that in its absence they can continue to grow and eventually spread to other organs.
A simpler form of testing individuals with risk factors for diabetes could improve diabetes prevention efforts by substantially increasing the number of individuals who complete testing and learn whether or not they are likely to develop diabetes.